公开(公告)号：EP4461724A1

公开(公告)日：2024-11-13

申请号：EP23737303.0

申请日：2023-01-06

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： ITO, Taisuke ,  OSAWA, Taisei

IPC分类号： C07C231/02 ,  C07C233/11 ,  C07C233/15 ,  C07C233/65 ,  C07C233/66 ,  C07C303/36 ,  C07C311/16 ,  C07D211/46 ,  C07D211/64 ,  C07D233/58 ,  C07D295/155 ,  C07D295/192 ,  C07D307/68

摘要： The present invention provides a method for producing an amide compound, comprising reacting a carboxylic acid compound and an amine compound in the presence of a condensing agent and a first base to obtain an amide compound, wherein the first base is a compound represented by formula A, and a molar ratio of the first base to the condensing agent (first base/condensing agent) is 1.8 or less.

公开(公告)号：EP4455158A1

公开(公告)日：2024-10-30

申请号：EP22911345.1

申请日：2022-12-22

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： YAMAMOTO, Yohei ,  KAMON, Hokuto ,  WATANABE, Miho ,  TSUTSUI, Haruka

IPC分类号： C07K14/52 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/19 ,  C12N15/62 ,  C12N15/63

摘要： The present disclosure relates to CXCR3 ligands having CXCR3-expressing-cell migration-inducing activity, and specifically to amino acid modifications and amino acid sequences that are important for CXCR3-expressing-cell migration-inducing activity.

公开(公告)号：EP4436603A1

公开(公告)日：2024-10-02

申请号：EP22898636.0

申请日：2022-11-25

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA ,  F. Hoffmann-La Roche AG

发明人： OZAWA, Takatoshi ,  YAMASHIRO, Mai ,  ITO, Hajime ,  YOSHIDA, Shunsuke ,  SMITH, Jillian ,  VODOPIVEC, Ivana ,  LENNON-CHRIMES, Sian ,  KLINGELSCHMITT, Gaelle ,  VON BUEDINGEN, Hans-Christian ,  SILBER BAUMANN, Hanna

IPC分类号： A61K39/395 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/573 ,  A61P25/00 ,  A61P37/06

CPC分类号： A61K31/5377 ,  A61K31/52 ,  A61P25/00 ,  A61K31/573 ,  A61K45/06 ,  C07K2317/2420130101 ,  C07K2317/7620130101 ,  C07K16/2866 ,  C07K2317/9020130101

公开(公告)号：EP4406546A1

公开(公告)日：2024-07-31

申请号：EP23799441.3

申请日：2023-04-19

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： NAKAE, Shinichi ,  TAKANO, Ryusuke ,  TANG, Hengmin ,  SAKURAI, Yuji

IPC分类号： A61K38/12 ,  A61K9/08 ,  A61K38/00 ,  A61K47/12 ,  A61K47/14 ,  A61K47/18 ,  A61K47/20

CPC分类号： A61K38/00 ,  A61K47/20 ,  A61K38/12 ,  A61K47/12 ,  A61K47/14 ,  A61K47/18 ,  A61K9/08

摘要： The present invention relates to a composition comprising a component (1) below, for combined use of a component (2) below:
(1) at least one or more peptide compounds selected from the group consisting of (i), (ii), and (iii) below:
(i) a peptide compound containing one or more N-substituted amino acid residues,
(ii) a peptide compound having ClogP of 4 or more and 25 or less, and
(iii) a peptide compound having a solubility of 10 mg/mL or less at 37°C and 1 atm in 50 mM phosphate buffer (pH 6.5); and

(2) at least one or more surfactants selected from the group consisting of (iv) and (v) below:
(iv) a surfactant having a linear alkylene structure and having 5 or more and 13 or less carbon atoms in the alkylene structure, and
(v) a surfactant having a carnitine residue.

公开(公告)号：EP4374877A2

公开(公告)日：2024-05-29

申请号：EP24161259.7

申请日：2015-09-11

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： Ohtake, Yoshihito ,  Okamoto, Naoki ,  Ono, Yoshiyuki ,  Kashiwagi, Hirotaka ,  Kimbara, Atsushi ,  Harada, Takeo ,  Hori, Nobuyuki ,  Murata, Yoshihisa ,  Tachibana, Kazutaka ,  Tanaka, Shota ,  Nomura, Kenichi ,  Ide, Mitsuaki ,  Mizuguchi, Eisaku ,  Ichida, Yasuhiro ,  Ohtomo, Shuichi ,  Horiba, Naoshi

IPC分类号： A61K45/06

CPC分类号： C07D403/12 ,  C07D405/14 ,  C07D413/14 ,  A61K45/00 ,  A61K31/19 ,  A61K31/4545 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/503 ,  A61K31/506 ,  A61K31/537 ,  A61K31/5377 ,  A61K31/734 ,  A61K33/08 ,  A61K33/10 ,  A61K33/24 ,  A61K33/26 ,  C07D401/06 ,  C07D401/12 ,  C07D237/04 ,  C07D403/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D498/08 ,  A61K33/244 ,  A61K45/06 ,  A61K31/24

摘要： The present invention provides a pharmaceutical composition containing, as an active ingredient, a dihydropyridazine-3,5-dione derivative or a salt thereof or a solvate of these, wherein the composition is administered in combination with a phosphorus adsorbent.

公开(公告)号：EP4373862A1

公开(公告)日：2024-05-29

申请号：EP22845886.5

申请日：2022-07-15

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： CHICHILI, Vishnu Priyanka Reddy ,  NAMBU, Takeru ,  IGAWA, Tomoyuki ,  YAMAMOTO, Yohei ,  SATO, Motohiko ,  HIRONIWA, NAOKA

IPC分类号： C07K19/00 ,  C07K14/54 ,  C07K16/24 ,  C12P21/02 ,  C40B40/10 ,  C12N15/13 ,  C12N15/62

CPC分类号： C12N15/1058 ,  C40B40/08 ,  C07K2319/5020130101 ,  C07K14/5434 ,  C07K16/244 ,  A61K2039/50520130101 ,  A61P35/00 ,  C07K2317/5620130101 ,  C07K2317/9220130101 ,  C07K2317/9420130101

公开(公告)号：EP4310191A3

公开(公告)日：2024-05-15

申请号：EP23195290.4

申请日：2013-06-14

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： IGAWA, Tomoyuki ,  HIRONIWA, Naoka ,  KADONO, Shojiro ,  MATSUO, Atsushi ,  KURAMOCHI, Taichi ,  MIMOTO, Futa

IPC分类号： C07K16/00 ,  A61K39/395 ,  C07K19/00 ,  C12N15/09 ,  C12P21/02

CPC分类号： C07K2317/5220130101 ,  C07K2317/7120130101 ,  C07K2317/7220130101 ,  C07K2319/3020130101 ,  C07K2317/9420130101 ,  C07K16/22 ,  C07K16/2848 ,  C07K2317/73220130101 ,  C07K16/00

摘要： The present inventors have successfully prepared an antibody Fc region dimer that has binding activity against each of an antigen and FcyR, but does not bind to the antigen and the FcyR at the same time, and a polypeptide comprising the Fc region dimer. The present invention enables the preparation of a multispecific binding polypeptide capable of avoiding an adverse reaction that may be caused by its binding to an antigen and FcyR at the same time. Thus, the present invention provides a polypeptide suitable as a drug.

公开(公告)号：EP4349840A2

公开(公告)日：2024-04-10

申请号：EP24154118.4

申请日：2017-09-26

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： YOSHINO, Hitoshi ,  TSUCHIYA, Satoshi ,  MATSUO, Atsushi ,  SATO, Tsutomu ,  NISHIMOTO, Masahiro ,  OGURI, Kyoko ,  OGAWA, Hiroko ,  NISHIMURA, Yoshikazu ,  FURUTA, Yoshiyuki ,  KASHIWAGI, Hirotaka ,  HORI, Nobuyuki ,  KAMON, Takuma ,  SHIRAISHI, Takuya ,  YOSHIDA, Shoshin ,  KAWAI, Takahiro ,  TANIDA, Satoshi ,  AOKI, Masahide

IPC分类号： C07D519/00

摘要： The present invention provides a a process for manufacturing a compound of formula (Ia), or a pharmaceutically acceptable salt thereof:

公开(公告)号：EP4342984A1

公开(公告)日：2024-03-27

申请号：EP22804747.8

申请日：2022-05-19

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： NOGUCHI, Yuki ,  OZEKI, Kazuhisa ,  SATO, Kazuki ,  NAOI, Sotaro ,  TSUTSUI, Haruka ,  OHMINATO, Noriaki

IPC分类号： C12N5/10 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50

摘要： The present invention provides a method for measuring in vitro pharmacokinetics of a molecule, the method including steps of: (a) contacting a molecule with a cell expressing FcRn in an aqueous medium to allow the cell to take up the molecule to be an uptake amount higher than 0.068 pmol/2 × 10 5 cells, in which step (a) has at least one feature selected from the following (i) to (iii): (i) a period of the contact of the molecule with the cell is 5 hours or more; (ii) the cell after the contact with the molecule is not washed under acidic conditions; and (iii) the cell expresses a target of the molecule on a surface of the cell; and (b) measuring in vitro pharmacokinetics of the molecule, in which the molecule contains an FcRn-binding domain, and the like.

公开(公告)号：EP4282428A3

公开(公告)日：2024-03-20

申请号：EP23193707.9

申请日：2009-01-09

申请人： The University of Tokyo ,  CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： ABURATANI, Hiroyuki ,  TSUTSUMI, Shuichi ,  NISHIMURA, Kunihiro ,  SAKUMOTO, Hirofumi ,  KAWAI, Shigeto

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  G01N33/53 ,  G01N33/574 ,  C12N15/09 ,  C12P21/08 ,  A61K39/00

摘要： Disclosed is an antibody capable of binding to Claudin-6 (CLDN6) which is expressed on the surface of a cell membrane. The antibody can recognize human CLDN6 occurring on the surface of a cell membrane in its native form, and has a cytotoxic activity (e.g., ADCC activity and a CDC activity) against a cancer cell line which expresses human CLDN6 at a high level. A conjugate of the antibody and a toxin has an inhibitory activity on the cell proliferation of a cancer cell line which expresses human CLDN6 at a high level. The expression of human CLDN6 is not observed in a normal tissue, but is increased in a tumor tissue (e.g., pulmonary adenocarcinoma, gastric cancer, ovarian cancer). The anti-CLDN6 antibody is expected to be highly accumulated in tumor in which human CLDN6 has been expressed at a high level, and therefore can be used as an extremely effective anti-tumor agent.